Orchestra BioMed Investor Relations Blog | May 2026
The receipt of $35 million in strategic capital from Medtronic and Ligand reflects continued partner alignment behind Orchestra BioMed’s pivotal-stage cardiovascular pipeline.
Orchestra BioMed Investor Relations Blog | April 2026
The second Breakthrough Device Designation awarded to AVIM Therapy underscores its potential in a defined high-risk population and supports an accelerated development pathway.
Orchestra BioMed Investor Relations Blog | April 2026
Recently presented clinical and mechanistic findings reinforce the potential of Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) to immediately reduce blood pressure and have a favorable cardiac hemodynamic impact, expanding its potential therapeutic relevance beyond hypertension into hypertensive heart disease.
Orchestra BioMed recently announced multiple scientific presentations highlighting the robust body of existing clinical findings from the Atrioventricular Interval Modulation (“AVIM”) Therapy program at the Technology Heart Failure and Therapeutics (“THT”) and Cardiovascular Research Technologies (“CRT”) 2026 Meetings. These discussions reinforce growing clinical interest in our novel, device-based approach to treating hypertension and reducing associated cardiovascular risk.
The recent acquisition of Vivasure Medical by Haemonetics follows over a decade of collaboration between Vivasure and Orchestra BioMed. Over that time, Orchestra worked alongside the Vivasure team through early-stage fundraising, clinical development and next-generation advancement of the PerQseal® technology, including during the formation and evolution of Vivasure’s strategic relationship with Haemonetics.
As 2025 comes to a close, I want to take the opportunity to reflect on a year of important achievements that puts Orchestra BioMed in a very strong position for the year to come. This year saw our Company make substantive clinical, strategic, and financial progress: we advanced execution of both of our pivotal trial-stage programs, we strengthened and clarified our strategic partnerships, and we secured nearly $150 million in capital and capital commitments on favorable terms.
This week, at the Innovation in Cardiovascular Intervention (“ICI”) meeting in Israel, Orchestra BioMed highlighted the strategic and clinical progress behind its two pivotal programs - Atrioventricular Interval Modulation Therapy (“AVIM Therapy”)and Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue SAB”).
To complement our two-part summary of Orchestra BioMed’s recent shareholder update call, we are highlighting the Q&A session that followed the prepared remarks. Given strong shareholder interest in the types of questions asked - and the additional clarity provided by management during the discussion - we believe a concise summary of the major themes will be helpful.
This post is Part 2 of 2 in our summary of Chairman and CEO David Hochman’s recent shareholder update call, which provided a detailed perspective on Orchestra BioMed’s progress through 2025.
This blog is the first of a two-part summary from Chairman and CEO David Hochman’s recent shareholder update call, which offered a detailed perspective on Orchestra BioMed’s progress through what has been a highly productive and strategically defining year.
While the Company’s third-quarter financial results reflect disciplined execution, the call focused not on quarterly numbers, but on how Orchestra BioMed’s financing, partnerships, and pivotal-stage programs are shaping long-term value creation.
In this first part, we summarize the discussion of recent financing success and strategic alignment — how Orchestra BioMed has strengthened its capital foundation and optimized partnerships to advance its flagship programs, AVIM Therapy and Virtue SAB, from a position of operational and financial strength.
